Ihowuliseleli OEM China CE Ephawulweyo SARS Antigen Rapid Uvavanyo Colloidal Gold

inkcazelo emfutshane:


  • Ixesha lovavanyo:10-15 imizuzu
  • Ixesha elisebenzayo:Iinyanga ezingama-24
  • Ukuchaneka:Ngaphezulu kwe-99%
  • Inkcazo:1/25 uvavanyo / ibhokisi
  • Ubushushu bokugcina :2℃-30℃
  • :
  • Iinkcukacha zeMveliso

    Iithegi zeMveliso

    Inkampani yethu igxininisa kulo lonke umgaqo-nkqubo womgangatho "wemveliso esemgangathweni isisiseko sokusinda kweshishini; ukuzaliseka komthengi kuya kuba yindawo yokujonga kunye nesiphelo senkampani; uphuculo oluzingisileyo kusukelo lwanaphakade lwabasebenzi" kunye nenjongo engaguqukiyo "yodumo lokuqala, umthengi kuqala" kwiWholesale yeOEM China CE Ephawulwe yi-SARS ye-Antigen eKhawulezayo yoVavanyo lwe-Colloidal kunye nokuphucula umgangatho weGold ulwaneliseko lwakho ngempumelelo. Ukuba unomdla kwizisombululo zethu, nceda uqhagamshelane nathi ngokukhululekileyo.
    Inkampani yethu igxininisa kulo lonke umgaqo-nkqubo womgangatho "wemveliso esemgangathweni isisiseko sokusinda kweshishini; ukuzaliseka komthengi kuya kuba yindawo yokujonga kunye nesiphelo senkampani; uphuculo oluzingisileyo kusukelo lwanaphakade lwabasebenzi" kunye nenjongo engaguqukiyo "yodumo lokuqala, abathengi kuqala"China SARS Antigen Test, Uvavanyo lwe-SARS-C0V2, Ngoku sicinge ngokunyanisekileyo ukunika i-arhente yophawu kwiindawo ezahlukeneyo kwaye umda wengeniso ye-arhente yeyona nto ibalulekileyo esiyikhathaleleyo. Wamkelekile bonke abahlobo kunye nabathengi ukuba bazibandakanye nathi. Sele sikulungele ukwabelana win-win corporation.
    CEA

    ikhola_conew1

     

    Iimveliso Iinkcukacha ikhowudi iyunithi uluhlu lomgca uluhlu lwereferensi Uluhlu lomgca
    Ikhithi yokuxilonga yeCarcino-embryonic antigen 25T/Ibhokisi Cea ng/ml 2-500 5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


  • Ngaphambili:
  • Okulandelayo: